$BGLC

$1.13 -$0.03 (2.59%) Close

$BGLC Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 2.9M shares outstanding

Who owns BGLC?

By type of holder

Institutions 0.5% Insiders 31.0% Everyone else 68.5%

Concentration Top 9 holders own 31.5%

Fidelion Diagnostics Pte. LTD. 13.4% · Tan Lee Su-Leng 11.6%

Institutional ownership

0.5%

+0.5 pts vs last qtr

Institutional holders

+1 vs last qtr

Net shares bought

+14.2K

by institutions in Q2 2026

New / sold out

2 / 1

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

HRT Financial LP NEW +14.3K
Caitong International Asset Management Co., Ltd NEW +1

Biggest sellers in Q2 2026

UBS Group AG −130
Wells Fargo & Company/mn SOLD OUT −1

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for BioNexus Gene Lab Corp in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2023–FY2024

+12.2%

+12.24% a year

Each share's claim on the business

−10.9%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $141K

over 2 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years0% 1–3 years0% Under 1 year100%

Quarterly turnover

3106.7%

of institutional shares changed hands

Top 10 managers, median time held

0 quarters

Super Investors

Investment managers reporting BGLC on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
HF HRT Financial LP	14.3K	0.49%	NEW	Q2 '26	0.0%
Shares held by quarter Peak holding14.3K (Q2'26) Change over 8 quarters+14.3K Share of the company0.490% HRT Financial LP's full portfolio →
UG UBS Group AG	101	0.00%	−130 (−56.3%)	Q1 '26	0.0%
Shares held by quarter Peak holding9.6K (Q2'25) Change over 8 quarters+101 Share of the company0.000% UBS Group AG's full portfolio →

HRT Financial LP

14.3K

% of company

0.49%

Change vs last qtr

NEW

Held since

Q2 '26

UBS Group AG

101

% of company

0.00%

Change vs last qtr

−130 (−56.3%)

Held since

Q1 '26

2 more super investors behind a free account

See every manager holding BioNexus Gene Lab Corp, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting BGLC on Form N-PORT; together they hold 0.1% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
FN Fidelity Nasdaq Composite Index Fund Fidelity Concord Street Trust	$5.49K	2.4K	0.08%	0.00%	May 31, 2026
BA Blackstone Alternative Multi-Strategy Fund Blackstone Alternative Investment Funds	$5.85	3	0.00%	0.00%	June 30, 2026

Fidelity Nasdaq Composite Index Fund

Fidelity Concord Street Trust

Position value

$5.49K

% of company

0.08%

% of the fund

0.00%

As of

May 31, 2026

Blackstone Alternative Multi-Strategy Fund

Blackstone Alternative Investment Funds

Position value

$5.85

% of company

0.00%

% of the fund

0.00%

As of

June 30, 2026

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
FD Fidelion Diagnostics Pte. LTD. Insider	392.3K	13.37%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company13.370% Fidelion Diagnostics Pte. LTD.'s insider activity →
TL Tan Lee Su-Leng 5%+ holder 13D · 11.5%	338.7K	11.55%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company11.550% Disclosed stake13D · 11.5% View the 13D/G filing →

Fidelion Diagnostics Pte. LTD.

Insider

392.3K

% of company

13.37%

Change vs last qtr

—

Held since

—

Tan Lee Su-Leng

5%+ holder13D · 11.5%

338.7K

% of company

11.55%

Change vs last qtr

—

Held since

—

4 more holders behind a free account

See every insider and 5%+ holder of BioNexus Gene Lab Corp.

Comments